- ISIN DE000A11QVV0
- Country Deutschland
Latest Reports
News Functions
Additional Functions
10 October 2024
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2023/2024
11 July 2024
Heidelberg Pharma AG
Half-yearly financial report 2023/2024
29 April 2024
Heidelberg Pharma AG
Q1 statement / Q1 financial report 2023/2024
25 April 2024
Heidelberg Pharma AG
Q1 Mitteilung / Q1 Finanzbericht 2023/2024
26 March 2024
Heidelberg Pharma AG
Annual financial report 2022/2023
Heidelberg Pharma AG
Jahresfinanzbericht 2022/2023
12 October 2023
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2022/2023
13 July 2023
Heidelberg Pharma AG
Half-yearly financial report 2022/2023
19 April 2023
Heidelberg Pharma AG
Q1 statement / Q1 financial report 2022/2023
28 March 2023
Heidelberg Pharma AG
Annual financial report 2021/2022
24 March 2023
Heidelberg Pharma AG
Jahresfinanzbericht 2021/2022
13 October 2022
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2021/2022
12 July 2022
Heidelberg Pharma AG
Half-yearly financial report 2021/2022
28 April 2022
Heidelberg Pharma AG
Q1 statement / Q1 financial report 2021/2022
31 March 2022
Heidelberg Pharma AG
Jahresfinanzbericht 2020/2021
29 March 2022
Heidelberg Pharma AG
Annual financial report 2020/2021
11 October 2021
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2020/2021
19 July 2021
Heidelberg Pharma AG
Q1 statement / Q1 financial report 2020/2021
Heidelberg Pharma AG
Half-yearly financial report 2020/2021
Heidelberg Pharma AG
Annual financial report 2019/2020
Latest News
News Functions
Additional Functions
6 November 2024
Heidelberg Pharma AG
Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
24 October 2024
Heidelberg Pharma AG
Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
10 October 2024
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
1 October 2024
Heidelberg Pharma AG
Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Heidelberg Pharma AG
Heidelberg Pharma AG Announces Updated Guidance
23 September 2024
Heidelberg Pharma AG
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024